Unlocking the value of personalised healthcare in Europe — breast cancer stratification

Through stratification, this simulation shows that there is great potential to improve the efficiency of treating breast cancer. By segmenting the female population at the age of 50 based on family history and genetic testing, our model shows a reduction in costs of breast cancer treatments by 37% with no loss of efficacy accomplished primarily through a 60% drop in incidence of metastatic stages of the disease. These programmes are not inexpensive, and require substantial upfront investments of roughly 2 billion GBP and continued annual investments of several hundred million GBP. However, our simulations show a positive NPV and ROI in approximately year 7 of the programme

Acute coronary syndrome: What is the cost-effectiveness of prevention, point-of-care technology and telemonitoring?

This study is a cost-analysis that calculates the impact of three interventions for patients identified as ‘at risk’ for Acute Coronary Syndrome - a cardio-vascular exercise programme, point-of-care digital diagnostics, and telemonitoring adherence tools. The methodology utilizes a model of the annualized costs of ACS for the entire treatment value chain, and measures the impact of the three interventions by the change in treatment cost, incremental net benefit, and QALY. The results demonstrate that the largest impact is measured when all three interventions are utilized simultaneously producing a cumulative savings of €4424 and 0.126 QALY per patient. We also find a significant decrease in Emergency Room visits by 15% and changes in rates of utilization of Catharization (−59%), Angioplasty (−59%), Bypass (−17%), Medication (−14%) and Rehabilitation (−13%)

Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation

After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014. Although it is a significant achievement to see the first asset being placed into human trials under an adaptive pathway, there is much to be learned regarding the multinational and multi-stakeholder effort that has driven the growing acceptance of MAPPs as a methodology and concept, as well as the need for continued and increasing international collaboration to foster the wider adoption of MAPPs. Changes in available science and technology, as well as a number of challenges in the current system, outlined in this paper, are transforming approaches to medicines development and approval. It is these challenges that have led directly to the groundbreaking MAPPs collaboration between the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms Initiative, the EMA, patient, payer and health technology assessment groups, the European Federation of Pharmaceutical Industries and Associations, and the Innovative Medicines Initiative—a European public-private partnership. This article examines the development of MAPPs, from inception of the concept, to the establishment of this trans-Atlantic initiative, and examines challenges for the future.SCOPUS: ar.jinfo:eu-repo/semantics/publishe